novartis_window

Novartis’ ligelizumab tops Xolair in chronic spontaneous urticaria

pharmafile | January 9, 2020 | News story | Research and Development Novartis, Xolair, ligelizumab 

Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair (omalizumab), also manufactured by the company, in the treatment of the skin condition chronic spontaneous urticaria (CSU).

The firm revealed that a new study determined that ligelizumab is more effective at inhibiting the major pathogenic IgE/FcεRI pathway in CSU compared to Xolair, binding to IgE in a different manner and with an 88-fold higher affinity.

“This mechanistic research study is a great step forward in understanding how different anti-IgE treatments can have qualitatively and functionally distinct inhibition profiles”, explained Dr Alexander Eggel of the University of Bern, Switzerland, and an investigator on the study.

“We were recently encouraged by previous clinical study results showing more patients are completely symptom-free from CSU with ligelizumab than Xolair,” added Eric Hughes, Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis. “This mechanistic study further supports those findings as we look to reimagine care to bring better treatment options for patients with CSU.”

Matt Fellows

Related Content

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …

kidney

Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …

Latest content